Anrotinib and bevacizumab are not the same, and their indications, pharmacological effects and adverse reactions are different. 1. Indications: Anrotinib is mainly applied to advanced small cell lung cancer, medullary thyroid cancer, some soft tissue sarcoma and other diseases; Bevacizumab is mostly used in the treatment of recurrent glioblastoma, hepatocellular carcinoma and other diseases. 2. Pharmacological effects: Anrotinib is a new type of target therapeutic drug, mainly targeting cancer cells, which will not harm normal cells, and it belongs to a kind of anti-tumor angiogenesis multi-targeted chlorine kinase inhibitor, which can play a therapeutic role by inhibiting the activity of VEGFR1-3, while bevacizumab can play a therapeutic role by inhibiting the neovascularization of the tumors. 3. Adverse reactions: Anrotinib will have hypertension, fatigue, diarrhea, loss of appetite and other adverse reactions; Bevacizumab adverse reactions are mostly gastrointestinal perforation, proteinuria, abdominal pain and so on. Follow the doctor’s instructions to take medication, do not stop taking medication without authorization, and go to the hospital in time for consultation.